Advertisement

Current Treatment Options in Psychiatry

, Volume 6, Issue 4, pp 401–411 | Cite as

Current Pharmacological Treatments for Childhood Onset OCD

  • Martin E. Franklin
  • Stephanie Eken
  • Sarah G. Turk Karan
  • Bradley C. RiemannEmail author
Child and Adolescent Psychiatry (M Singh and M Goldsmith, Section Editors)
  • 13 Downloads
Part of the following topical collections:
  1. Topical Collection on Child and Adolescent Psychiatry

Abstract

Purpose of review

Obsessive-compulsive disorder (OCD) is a chronic condition associated with substantial morbidity, comorbidity, and functional impairment in affected youths. Fortunately, efficacy has been established for multiple pharmacotherapies; however, treatment response remains neither universal nor complete; hence, treatment development efforts continue.

Recent findings

This review aims to examine evidence for recent trials examining augmentation strategies for partial responders to serotonin reuptake inhibitors (SRIs), the efficacy of adding D-cycloserine (DCS) to cognitive behavioral therapy (CBT), interventions for OCD symptoms associated with infection, and a meta-analytic view of SRI efficacy and dose-response outcomes.

Summary

Augmentative treatment with SRIs or additional CBT confers additional benefit in CBT partial responders; however, DCS augmentation does not enhance CBT outcomes. Further treatment development is needed to establish effective interventions for infection-related OCD symptoms, and an SRI dose-response curve does not appear to be evident when examining across multiple SRI trials. Implications of these finding for next-stage research efforts and clinical practice are considered.

Keywords

Obsessive-compulsive disorder Pediatrics Pharmacotherapy Augmentation 

Notes

Compliance with Ethical Standards

Conflict of Interest

Martin E. Franklin declares that he has no conflict of interest. Stephanie Eken declares that she has no conflict of interest. Sarah G. Turk Karan declares that she has no conflict of interest. Bradley C. Riemann declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    • Ivarsson T, Skarphedinsson G, Kornor H, Axelsdottir B, Biedilae S, Heyman I, et al. The place of and evidence for serotonin reputake inhibitors (SRIs) for obsessive compulsive disorder (OCD) in children and adolescents: views based on a systematic review and meta-analysis. Psychiatry Research. 2015;227:93–103 Comprehensive review and meta-analysis of pharmacotherapies for pediatric OCD.CrossRefGoogle Scholar
  2. 2.
    Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, … Leckman JF. Children’s Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 1999: 36:844-52.CrossRefGoogle Scholar
  3. 3.
    • Franklin ME, Kratz HE, Freeman JB, Ivarsson T, Heyman I, Sookman D, … March J. Cognitive-behavioral therapy for pediatric obsessive-compulsive disorder: empirical review and clinical recommendations. Psychiatry Res 2015:227: 78-92. Comprehensive review of CBT literature for pediatric OCD as well as combined treatment trials (SRIs + CBT).CrossRefGoogle Scholar
  4. 4.
    Franklin ME, Sapyta J, Freeman JB, Khanna M, Compton S, Almirall D, … March JS. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the pediatric OCD treatment study II (POTS II) randomized controlled trial. JAMA 2011:306: 1224-32.CrossRefGoogle Scholar
  5. 5.
    • O’Neill JO, Piacentini J, Chang S, Ly R, Lai TM, Armstrong CC, et al. Glutamate in pediatric obsessive-compulsive disorder and response to cognitive-behavioral therapy: randomized clinical trial. Neuropsychopharmacology. 2017;42:2414–22 Clinical trial examining Glu levels before and after CBT; model study for integrating neurobiological and behavioral findings in accordance with the RdoC model espoused at NIMH.CrossRefGoogle Scholar
  6. 6.
    Skarphedinsson G, Weidle B, Thomsen PH, Dahl K, Torp NC, Nissen JB, et al. Continued cognitive-behavior therapy versus sertraline for children and adolescents with obsessive-compulsive disorder that were non-responders to cognitive-behavioral therapy: a randomized controlled trial. Eur Child Adolesc Psychiatry. 2015;24:591–602.CrossRefGoogle Scholar
  7. 7.
    Melin K, Skarphedinsson G, Thomsen PH, Weidle B, Torp NC, Valderhaug R, Hojgaard DRMA, Hybel KA, Nissen JB, Jensen S, Dahl K, Skarsater I, Haugland B S, Ivarsson T. Treatment gains are sustainable in pediatric obsessive-compulsive disorder: three-year follow-up from the NordLOTS. J Am Acad Child Adolesc Psychiatry 2019.  https://doi.org/10.1016/j.jaac.2019.01.010
  8. 8.
    Ivarsson T, Thomsen PH, Dahl K, Valderhaug R, Weidle B, Becker Nissen J, et al. The rationale and some features of the Nordic Long-Term OCD Treatment Study (NordLOTS) in childhood and adolescence. Child Youth Care Forum. 2010;39:91–9.CrossRefGoogle Scholar
  9. 9.
    Torp NC, Dahl K, Skarphedinsson G, Thomsen PH, Valderhaug R, Weidle B, Franklin ME, … Ivarsson T. Effectiveness of cognitive behavior treatment for pediatric obsessive-compulsive disorder: acute outcomes from the nordic long-term OCD treatment study (NordLOTS). Behav Res Ther 2015:64: 15-23.CrossRefGoogle Scholar
  10. 10.
    Kushner MG, Kim SW, Donahue C, et al. d-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry. 2007;62:835–8.CrossRefGoogle Scholar
  11. 11.
    • Storch EA, Wilhelm S, Sprich S, Henin A, Micco J, Small BJ, et al. Efficacy of augmentation of cognitive behavior therapy with weight-adjusted d-cycloserine vs placebo in pediatric obsessive-compulsive disorder a randomized clinical trial. JAMA Psychiatry. 2016;73:779–88 Multisite randomized controlled trial examining DCS augmentation of CBT in pediatric OCD.CrossRefGoogle Scholar
  12. 12.
    Schade S, Paulus W. D-cycloserine in neuropsychiatric diseases: a systematic review. Int Jnl Neuropsychopharm. 2016;19:1–7.CrossRefGoogle Scholar
  13. 13.
    Williams KA, Swedo SE, Farmer CA, Grantz H, D’Souza P, Hommer R, et al. Randomized, controlled trial of intravenous immunoglobulin for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. Journal of the American Academy of Child & Adolescent Psychiatry. 2016;55:860–7.CrossRefGoogle Scholar
  14. 14.
    Giulino L, Gammon P, Sullivan K, Franklin ME, Foa EB, Maid R, et al. Is parental report of upper respiratory infection at the onset of obsessive-compulsive disorder suggestive of pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection? Journal of Child and Adolescent Psychopharmacology. 2002;12:157–64.CrossRefGoogle Scholar
  15. 15.
    Perlmutter SJ, Leitman SF, Garvey MA, et al. Therapeutic plasma exchange and intravenous immunoglobin for obsessive-compulsive disorder and tic disorders in childhood. Lancet. 1999;354:1153–8.CrossRefGoogle Scholar
  16. 16.
    Murphy TK, et al. A double-blind randomized placebo-controlled pilot study of azithromycin in youth with acute-onset obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology. 2017;27:640–51.CrossRefGoogle Scholar
  17. 17.
    Foa EB, Kozak MJ. Emotional processing of fear: exposure to corrective information. Psychological Bulletin. 1986;99:20–35.CrossRefGoogle Scholar
  18. 18.
    Mowrer OA. A stimulus-response analysis of anxiety and its role as a reinforcing agent. Psychological Review. 1939;46:553–65.CrossRefGoogle Scholar
  19. 19.
    Mowrer OA. Learning theory and behavior. New York: Wiley; 1960.CrossRefGoogle Scholar
  20. 20.
    • Varigonda AL, Jakubovski E, Bloch MH. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 2016;55:851–9 Meta-analysis attesting to the efficacy of SRIs for pediatric OCD that also failed to find a clear dose-response effect.Google Scholar
  21. 21.
    Freeman J, Sapyta J, Garcia A, Compton, S, Khanna M, Flessner C, … Franklin ME. Family-based treatment of early childhood obsessive-compulsive disorder: the pediatric obsessive-compulsive disorder treatment study for young children (POTS Jr.)—A randomized clinical trial. JAMA Psychiatry 2014:71: 689-98.CrossRefGoogle Scholar
  22. 22.
    Pediatric OCD Treatment Study Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004;292:1969–76.CrossRefGoogle Scholar
  23. 23.
    Leonard RC, Franklin ME, Wetterneck CT, Riemann BC, Simpson HB, Kinnear K,… Lake PM. Residential treatment outcomes for adolescents with obsessive-compulsive disorder. Psychotherapy Res 2016:26: 727-36.CrossRefGoogle Scholar
  24. 24.
    Franklin ME, Kay, B, Cook J, Riemann B, Katz J, et al. Machine learning in pediatric OCD: methods and application. 2019. Manuscript in preparation.CrossRefGoogle Scholar
  25. 25.
    • Insel TR, Cuthbert BN, Garvey MA, Heinssen RK, Pine DS. Research Domain Criteria (RdoC): toward a new classification framework for research on mental disorders. American Journal of Psychiatry. 2010;167:748–51 Presentation of the RDoC model and its implications for next-stage clinical research trials in the US.Google Scholar
  26. 26.
    Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30:1735–40.CrossRefGoogle Scholar
  27. 27.
    Franklin ME, Himle MB. “Evidence-based psychosocial treatments for tic disorders”: theoretical and treatment implications. Clinical Psychology: Science and Practice. 2007;14:274–8.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Martin E. Franklin
    • 1
    • 2
  • Stephanie Eken
    • 1
  • Sarah G. Turk Karan
    • 3
  • Bradley C. Riemann
    • 1
    Email author
  1. 1.Rogers Behavioral HealthOconomowocUSA
  2. 2.University of Pennsylvania School of MedicinePhiladelphiaUSA
  3. 3.Brandeis UniversityWalthamUSA

Personalised recommendations